Diabetic nephropathy (DN) or diabetic kidney disease is a syndrome characterized by the presence of pathological quantities of urine albumin excretion, diabetic glomerular lesions, and loss of glomerular filtration rate (GFR) in diabetics. Not all diabetics develop DN and in those who do, progression is variable. The main modifiable risks are hypertension, glycemic control, and dyslipidemia.
“Diabetic Nephropathy Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Nephropathy Market.
The Diabetic Nephropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Diabetic Nephropathy Pipeline Report:
- Companies across the globe are diligently working toward developing novel Diabetic Nephropathy treatment therapies with a considerable amount of success over the years. Diabetic Nephropathy Key players such as – ZyVersa Therapeutics, XORTX Therapeutics Inc., Inversago Pharma, Caladrius Biosciences, Inc., Goldfinch Bio, AstraZeneca, Boehringer Ingelheim, CSL Behring, Reata Pharmaceutical, and others, are developing therapies for the Diabetic Nephropathy treatment
- Diabetic Nephropathy Emerging therapies such as – VAR 200-03, XRx-225, INV-202, CLBS201, GFB-024, MEDI-3506, BI-685509, CSL346, Bardoxolone methyl, and others are expected to have a significant impact on the Diabetic Nephropathy market in the coming years.
- In May 2018, Kyowa Kirin Co., Ltd. initiated a Phase III study to demonstrate the efficacy of multiple oral doses of RTA 402 (5, 10, or 15 mg) administered once daily in patients with diabetic kidney disease (DKD) using the time to onset of a ≥ 30% decrease in estimated glomerular filtration rate calculated from serum creatinine (eGFR) from baseline or end-stage renal disease (ESRD) as an indicator in a randomized, double-blind, placebo-controlled study; the safety of RTA 402 will also be evaluated
Diabetic Nephropathy Pipeline Therapeutics Assessment
- Diabetic Nephropathy Assessment by Product Type
- Diabetic Nephropathy By Stage and Product Type
- Diabetic Nephropathy Assessment by Route of Administration
- Diabetic Nephropathy By Stage and Route of Administration
- Diabetic Nephropathy Assessment by Molecule Type
- Diabetic Nephropathy by Stage and Molecule Type
DelveInsight’s Diabetic Nephropathy Report covers around products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Emerging Diabetic Nephropathy Drugs Under Different Phases of Clinical Development Include:
- VAR 200-03: ZyVersa Therapeutics
- XRx-225: XORTX Therapeutics Inc.
- INV-202: Inversago Pharma
- CLBS201: Caladrius Biosciences, Inc.
- GFB-024: Goldfinch Bio
- MEDI-3506: AstraZeneca
- BI-685509: Boehringer Ingelheim
- CSL346: CSL Behring
- Bardoxolone methyl: Reata Pharmaceuticals
Diabetic Nephropathy Pipeline Analysis:
The Diabetic Nephropathy pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the Diabetic Nephropathy treatment with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Nephropathy Treatment.
- Diabetic Nephropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Diabetic Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Nephropathy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Diabetic Nephropathy product details are provided in the report. Download the Diabetic Nephropathy pipeline report to learn more about the emerging Diabetic Nephropathy therapies
Diabetic Nephropathy Pipeline Market Drivers
- Rise in the incidence of diabetes and obesity
- Surge in the number of different drug discovery studies being assessed
- Demand for innovative drugs and novel therapies
Diabetic Nephropathy Pipeline Market Barriers
- Stringent regulatory requirements
- Lack of comprehensive therapeutic management
Get a Free Sample PDF Report to know more about Diabetic Nephropathy Pipeline Assessment
Scope of Diabetic Nephropathy Pipeline Drug Insight
- Coverage: Global
- Key Diabetic Nephropathy Companies: ZyVersa Therapeutics, XORTX Therapeutics Inc., Inversago Pharma, Caladrius Biosciences, Inc., Goldfinch Bio, AstraZeneca, Boehringer Ingelheim, CSL Behring, Reata Pharmaceutical, and others
- Key Diabetic Nephropathy Therapies: VAR 200-03, XRx-225, INV-202, CLBS201, GFB-024, MEDI-3506, BI-685509, CSL346, Bardoxolone methyl, and others
- Diabetic Nephropathy Therapeutic Assessment: Diabetic Nephropathy current marketed and Diabetic Nephropathy emerging therapies
- Diabetic Nephropathy Market Dynamics: Diabetic Nephropathy market drivers and Diabetic Nephropathy market barriers
Request for Sample PDF Report for Diabetic Nephropathy Pipeline Assessment and clinical trials
Table of Contents
|1||Diabetic Nephropathy Report Introduction|
|2||Diabetic Nephropathy Executive Summary|
|3||Diabetic Nephropathy Overview|
|4||Diabetic Nephropathy- Analytical Perspective In-depth Commercial Assessment|
|5||Diabetic Nephropathy Pipeline Therapeutics|
|6||Diabetic Nephropathy Late Stage Products (Phase II/III)|
|7||Diabetic Nephropathy Mid Stage Products (Phase II)|
|8||Diabetic Nephropathy Early Stage Products (Phase I)|
|9||Diabetic Nephropathy Preclinical Stage Products|
|10||Diabetic Nephropathy Therapeutics Assessment|
|11||Diabetic Nephropathy Inactive Products|
|12||Company-University Collaborations (Licensing/Partnering) Analysis|
|13||Diabetic Nephropathy Key Companies|
|14||Diabetic Nephropathy Key Products|
|15||Diabetic Nephropathy Unmet Needs|
|16||Diabetic Nephropathy Market Drivers and Barriers|
|17||Diabetic Nephropathy Future Perspectives and Conclusion|
|18||Diabetic Nephropathy Analyst Views|
Download Sample PDF Report to know more about Diabetic Nephropathy drugs and therapies
DelveInsight is a leading Business Consultant, and Market Research Firm focusedexclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States